IO Biotech, Inc.·Healthcare

IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received an average rating of "Reduce" from the five analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 12-month price objective among analysts

IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received a consensus rating of "Reduce" from the five research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average twelve-month price target

IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short interest in February. As of February 13th, there was short interest totaling 4,262,939 shares, a drop of 20.9% from the January 29th total of 5,390,908 shares. Approximately 6.1% of the company's stock are sold short. Based on an
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.